miR-Test: A Blood Test for Lung Cancer Early Detection
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Lung cancer is the leading cause of cancer death worldwide. Low-dose computed tomography screening (LDCT) was recently shown to anticipate the time of diagnosis, thus reducing lung cancer mortality. However, concerns persist about the feasibility and costs of large-scale LDCT programs. Such concerns may be addressed by clearly defining the target "high-risk" population that needs to be screened by LDCT. We recently identified a serum microRNA signature (the miR-Test) that could identify the optimal target population. Here, we performed a large-scale validation study of the miR-Test in high-risk individuals (n = 1115) enrolled in the Continuous Observation of Smoking Subjects (COSMOS) lung cancer screening program. The overall accuracy, sensitivity, and specificity of the miR-Test are 74.9% (95% confidence interval [CI] = 72.2% to 77.6%), 77.8% (95% CI = 64.2% to 91.4%), and 74.8% (95% CI = 72.1% to 77.5%), respectively; the area under the curve is 0.85 (95% CI = 0.78 to 0.92). These results argue that the miR-Test might represent a useful tool for lung cancer screening in high-risk individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
The widespread regulation of microRNA biogenesis, function and decay
Krol, J., Loedige, I., & Filipowicz, W. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2843 · Cited by 4,672
Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., Guo, J., Zhang, Y., Chen, J., Guo, X., et al. (2008) · Cell Research · doi:10.1038/cr.2008.282 · Cited by 4,560
Cell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. B., & Pantel, K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3066 · Cited by 2,891
Early Lung Cancer Action Project: overall design and findings from baseline screening
Henschke, C. I., McCauley, D. I., Yankelevitz, D. F., Naidich, D. P., McGuinness, G., Miettinen, O. S., Libby, D. M., Pasmantier, M. W., Koizumi, J., Altorki, N. K., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)06093-6 · Cited by 2,508
Survival of Patients with Stage I Lung Cancer Detected on CT Screening
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa060476 · Cited by 1,706
Kroh, E. M., Parkin, R. K., Mitchell, P. S., & Tewari, M. (2010) · Methods · doi:10.1016/j.ymeth.2010.01.032 · Cited by 1,175
Outcome signature genes in breast cancer: is there a unique set?
Ein-Dor, L., Kela, I., Getz, G., Givol, D., & Domany, E. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bth469 · Cited by 802
Hu, Z., Chen, X., Zhao, Y., Tian, T., Jin, G., Shu, Y., Chen, Y., Xu, L., Zen, K., Zhang, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9342 · Cited by 798
Boeri, M., Verri, C., Conte, D., Roz, L., Modena, P., Facchinetti, F., Calabrò, E., Croce, C. M., Pastorino, U., & Sozzi, G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100048108 · Cited by 722
Analysis of Circulating MicroRNA: Preanalytical and Analytical Challenges
McDonald, J. S., Milosevic, D., Reddi, H. V., Grebe, S. K., & Algeciras-Schimnich, A. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.157198 · Cited by 679
Cost-Effectiveness of CT Screening in the National Lung Screening Trial
Black, W. C., Gareen, I. F., Soneji, S. S., Sicks, J. D., Keeler, E. B., Aberle, D. R., Naeim, A., Church, T. R., Silvestri, G. A., Gorelick, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312547 · Cited by 544
Sozzi, G., Boeri, M., Rossi, M., Verri, C., Suatoni, P., Bravi, F., Roz, L., Conte, D., Grassi, M., Sverzellati, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.4357 · Cited by 436
Plasma microRNAs as potential biomarkers for non-small-cell lung cancer
Shen, J., Todd, N. W., Zhang, H., Yu, L., Lingxiao, X., Mei, Y., Guarnera, M., Liao, J., Chou, A., Lu, C. L., et al. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2010.194 · Cited by 383
Bianchi, F., Nicassio, F., Marzi, M., Belloni, E., Dall'Olio, V., Bernard, L., Pelosi, G., Maisonneuve, P., Veronesi, G., & Di Fiore, P. P. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100154 · Cited by 351
Self-citationPlasma processing conditions substantially influence circulating microRNA biomarker levels
Cheng, H. H., Yi, H. S., Kim, Y., Kroh, E. M., Chien, J. W., Eaton, K. D., Goodman, M. T., Tait, J. F., Tewari, M., & Pritchard, C. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064795 · Cited by 317
Circulating micro‐RNA expression profiles in early stage nonsmall cell lung cancer
Heegaard, N. H. H., Schetter, A. J., Welsh, J. A., Yoneda, M., Bowman, E. D., & Harris, C. C. (2012) · International Journal of Cancer · doi:10.1002/ijc.26153 · Cited by 288
Veronesi, G., Bellomi, M., Mulshine, J. L., Pelosi, G., Scanagatta, P., Paganelli, G., Maisonneuve, P., Preda, L., Leo, F., Bertolotti, R., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.01.001 · Cited by 176
Self-citationSerum microRNA Biomarkers for Detection of Non-Small Cell Lung Cancer
Hennessey, P. T., Sanford, T., Choudhary, A., Mydlarz, W. W., Brown, D., Adai, A. T., Ochs, M. F., Ahrendt, S. A., Mambo, E., & Califano, J. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032307 · Cited by 173
Goulart, B. H. L., Bensink, M. E., Mummy, D. G., & Ramsey, S. D. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0023 · Cited by 134
Dampening Enthusiasm for Circulating MicroRNA in Breast Cancer
Leidner, R. S., Li, L., & Thompson, C. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057841 · Cited by 115
MicroRNAs in Body Fluids as Biomarkers for Non-Small Cell Lung Cancer: A Systematic Review
Huang, Y., Hu, Q., Deng, Z., Hang, Y., Wang, J., & Wang, K. (2014) · Technology in Cancer Research & Treatment · doi:10.7785/tcrt.2012.500377 · Cited by 32
MicroRNA biomarkers in lung cancer: MiRacle or quagMiRe?
Yendamuri, S., & Kratzke, R. A. (2011) · Translational research · doi:10.1016/j.trsl.2010.12.015 · Cited by 23
Cited by
Current and future perspectives of liquid biopsies in genomics-driven oncology
Heitzer, E., Haque, I. S., Roberts, C. E. S., & Speicher, M. R. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0071-5 · Cited by 1,557
Non-coding RNAs in disease: from mechanisms to therapeutics
Nemeth, K., Bayraktar, R., Ferracin, M., & Calin, G. A. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-023-00662-1 · Cited by 885
Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments
Lone, S. N., Nisar, S., Masoodi, T., Singh, M., Rizwan, A., Hashem, S., El-Rifai, W., Bedognetti, D., Batra, S. K., Haris, M., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01543-7 · Cited by 819
Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 568
Self-citationBiomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges
Seijo, L. M., Peled, N., Ajona, D., Boeri, M., Field, J. K., Sozzi, G., Pio, R., Zulueta, J. J., Spira, A., Massion, P. P., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.023 · Cited by 539
Metadata
- Authors
- Montani, F., Marzi, M. J., Dezi, F., Dama, E., Carletti, R. M., Bonizzi, G., Bertolotti, R., Bellomi, M., Rampinelli, C., Maisonneuve, P., Spaggiari, L., Veronesi, G., Nicassio, F., Di Fiore, P. P., & Bianchi, F.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-03-20
- Volume
- 107
- Issue
- 6
- Pages
- djv063-djv063
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2118342212
- Cited by
- 278
- References
- 23
- FWCI
- 9.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.